The Bay Area Tumor Institute Community Clinical Oncology Program (BATI-CCOP) is a consortium of 6 community and county hospitals in Greater Oakland, California. It was founded in 1979 as a CGOP and converted to CCOP status in 1989. With a special emphasis on the recruitment of minority, low Income, pediatric, non-English-speaking, and female populations in three Bay Area Counties, the BATI-CCOP enables cancer patients and the general "at risk" population to participate in the clinical, cancer control and prevention research of CALGB, SWOG, NSABP, RTOG, CTSU, COG, and HLMCC. The long-term objectives and specific aims of the BATI-CCOP include accrual to therapeutic trials at higher rates than comparable CCOPs, accrual of minority and pediatric patients at higher rates than all other CCOPs, aggressive cancer control recruitment that exceeds NCI's cancer control research requirements, and increased interaction with research bases. The CCOP will continue to accrue 95% of all eligible pediatric oncology patients in the region and will continue to excel n the recruitment of minority and female participants, essentially enabling the BATI-CCOP to fulfill the requirements of all three types of CCOP's (an adult CCOP, a Minority-Based CCOP, and a Pediatric CCOP). The CCOP will also continue to exceed NCI mandates and remain the Bay Area leader in accrual to cancer prevention and control trials. The BATI-CCOP offers a successful long-term track record, an organized and committed medical community, experienced physician investigators, institutional and financial support from the Bay Area Tumor Institute, and unusual access to African American, Hispanic, Asian, pediatric, underserved, and female populations.
This research seeks to improve public health by enabling physicians and cancer patients to participate in clinical trials research. The research outcomes are expected to lead to the identification and dissemination of improved methods to diagnose, treat, or prevent cancer.
|Yao, S; Sucheston, L E; Zhao, H et al. (2014) Germline genetic variants in ABCB1, ABCC1 and ALDH1A1, and risk of hematological and gastrointestinal toxicities in a SWOG Phase III trial S0221 for breast cancer. Pharmacogenomics J 14:241-7|
|Coleman, Robert L; Moon, James; Sood, Anil K et al. (2014) Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer 50:1638-48|
|Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61|
|Zirpoli, Gary R; Brennan, Patrick M; Hong, Chi-Chen et al. (2013) Supplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat 137:903-13|
|Schott, Anne F; Barlow, William E; Albain, Kathy S et al. (2012) Phase II trial of simple oral therapy with capecitabine and cyclophosphamide in patients with metastatic breast cancer: SWOG S0430. Oncologist 17:179-87|
|Sucheston, Lara E; Zhao, Hua; Yao, Song et al. (2011) Genetic predictors of taxane-induced neurotoxicity in a SWOG phase III intergroup adjuvant breast cancer treatment trial (S0221). Breast Cancer Res Treat 130:993-1002|
|Iqbal, S; Goldman, B; Fenoglio-Preiser, C M et al. (2011) Southwest Oncology Group study S0413: a phase II trial of lapatinib (GW572016) as first-line therapy in patients with advanced or metastatic gastric cancer. Ann Oncol 22:2610-5|
|Blanchard, Elizabeth M; Moon, James; Hesketh, Paul J et al. (2011) Comparison of platinum-based chemotherapy in patients older and younger than 70 years: an analysis of Southwest Oncology Group Trials 9308 and 9509. J Thorac Oncol 6:115-20|
|Smith, David C; Tangen, Cathy M; Van Veldhuizen Jr, Peter J et al. (2011) Phase II evaluation of early oral estramustine, oral etoposide, and intravenous paclitaxel combined with hormonal therapy in patients with high-risk metastatic prostate adenocarcinoma: Southwest Oncology Group S0032. Urology 77:1172-6|
|Livingston, Robert B; Barlow, William E; Kash, Joseph J et al. (2011) SWOG S0215: a phase II study of docetaxel and vinorelbine plus filgrastim with weekly trastuzumab for HER2-positive, stage IV breast cancer. Breast Cancer Res Treat 130:123-31|
Showing the most recent 10 out of 48 publications